ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2841

Apremilast for Behçet’s Syndrome: Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study in a Japanese Subgroup

Mitsuhiro Takeno1, Yoshiya Tanaka2, Hajime Kono3, Shouji Sugii4, Mitsumasa Kishimoto5, Sue Cheng6, Shannon McCue6, Maria Paris6 and Hiroaki Dobashi7, 1Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 2University of Occupational and Environmental Health, Kitakyushu, Japan, 3Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, 4Department of Rheumatology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, 5Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, 6Celgene Corporation, Summit, NJ, 7Internal Medicine Division of Hematology, Rheumatology, and Respiratory Medicine, Kagawa University, Kagawa, Japan

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Behcet's syndrome, clinical trials and ulcers, Japanese

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, October 23, 2018

Session Title: 5T093 ACR Abstract: Vasculitis–Non-ANCA-Assocd & Rel D/Os II: Novel Diagnostics & THRs (2838–2843)

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Apremilast, an oral phosphodiesterase 4 inhibitor, demonstrated efficacy in a global, phase III, multicenter, randomized, double-blind, placebo-controlled study in patients with Behçet’s syndrome and active oral ulcers previously treated with ≥1 non-biologic therapy. A subgroup analysis was performed for Japanese patients in this study. We assessed the efficacy and safety of apremilast compared with placebo over 12 weeks in the subgroup of Japanese patients with Behçet’s syndrome in the study.

Methods: In the global study, 207 patients with Behçet’s syndrome were randomized (1:1) to apremilast 30 mg BID (n=104) or placebo (n=103) for 12 weeks, followed by a 52-week active-treatment phase. Patients were stratified by region (Japan and “Other”). Patients had active Behçet’s syndrome, with ≥3 oral ulcers at randomization or ≥2 oral ulcers at screening and randomization without major organ involvement. The primary endpoint was the area under the curve (AUCWk0-12) for the total number of oral ulcers over 12 weeks. Additional endpoints included the assessments of oral ulcers, including pain, overall disease activity (Behçet’s Syndrome Activity Score [BSAS] and Behçet’s Disease Current Activity Form [BDCAF]), and quality of life (QoL) at Week 12. The primary and secondary variables in the Japanese subset analysis were pre-specified without adjustment for multiplicity. Nominal P values are presented.

Results: A total of 39 patients were included in the Japanese subgroup (placebo: n=20; apremilast: n=19). The subgroup analysis showed that the AUCWk0-12 for oral ulcers was significantly lower in the apremilast group compared with the placebo group over 12 weeks (Table), which is consistent with the findings of the overall study population (129.5 vs. 222.1; P<0.0001). Similarly, as observed in the overall population, significantly greater improvements were shown in complete response rate of oral ulcers and maintenance of complete response of oral ulcers, time to oral ulcer resolution, and BSAS at Week 12 in the apremilast group. Numerical improvements were observed in oral ulcer pain, BDCAF, and QoL at Week 12 in the apremilast group; unlike the overall population, significance was not achieved, likely due to the limitation of the small sample size. Treatment-emergent adverse events (AEs) were comparable between the apremilast (73.7%) and placebo (75.0%) treatment groups. One serious AE (migraine) was reported with apremilast treatment. No AEs led to discontinuation.

Conclusion: The Japanese subgroup analysis showed that apremilast reduced the number of oral ulcers and overall disease activity and had favorable effects on oral ulcer pain and QoL in patients with Behçet’s syndrome and active oral ulcers over 12 weeks. The safety profile was consistent with the known safety profile of apremilast, and results were consistent with findings in the overall study population.


Disclosure: M. Takeno, Celgene Corporation, 2; Y. Tanaka, Daiichi-Sankyo, Astellas, Pfizer, Mitsubishi-Tanabe, Bristol-Myers, Chugai, YL Biologics, Eli Lilly, Sanofi, Janssen, UCB, 8,Mitsubishi-Tanabe, Takeda, Bristol-Myers, Chugai, Astellas, Abbvie, MSD, Daiichi-Sankyo, Pfizer, Kyowa- Kirin, Eisai, Ono, 2; H. Kono, Celgene Corporation, 2; S. Sugii, Bristol-Meyers Squibb, Tanabe Mitsubishi Pharma, Chugai Pharmaceutical Co., Takeda Pharmaceutical Co., Pfizer, AYUMI Pharmaceutical Co, 8; M. Kishimoto, None; S. Cheng, Celgene Corporation, 3; S. McCue, Celgene Corporation, 3; M. Paris, Celgene Corporation, 3; H. Dobashi, None.

To cite this abstract in AMA style:

Takeno M, Tanaka Y, Kono H, Sugii S, Kishimoto M, Cheng S, McCue S, Paris M, Dobashi H. Apremilast for Behçet’s Syndrome: Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study in a Japanese Subgroup [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/apremilast-for-behcets-syndrome-results-from-a-phase-iii-randomized-double-blind-placebo-controlled-study-in-a-japanese-subgroup/. Accessed August 12, 2022.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/apremilast-for-behcets-syndrome-results-from-a-phase-iii-randomized-double-blind-placebo-controlled-study-in-a-japanese-subgroup/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies